Blood-derived APLP1+ extracellular vesicles are potential biomarkers for the early diagnosis of brain diseases
2025

Blood-derived APLP1+ extracellular vesicles as biomarkers for brain diseases

publication 10 minutes Evidence: high

Author Information

Author(s): Choi Yuri, Park Jae Hyun, Jo Ala, Lim Chul-Woo, Park Ji-Min, Hwang Jin Woo, Lee Kang Soo, Kim Young-Sang, Lee Hakho, Moon Jisook

Primary Institution: Department of Biotechnology, College of Life Science, CHA University, Gyeonggi-do, Republic of Korea.

Hypothesis

Can APLP1+ extracellular vesicles from blood serve as reliable biomarkers for the early diagnosis of brain diseases?

Conclusion

APLP1+ extracellular vesicles from blood can be used as noninvasive biomarkers for the early diagnosis of neurodegenerative diseases.

Supporting Evidence

  • APLP1+ EVs were confirmed to be of cerebral origin through RNA expression patterns.
  • Validation with Thy-1 GFP M line mice demonstrated coexpression of APLP1 and GFP in brain-derived EVs.
  • APLP1+ EVs showed significant enrichment in glioblastoma patient samples compared to healthy controls.

Takeaway

Scientists found a new way to detect brain diseases early by looking for special proteins in tiny bubbles in the blood.

Methodology

The study involved isolating APLP1+ extracellular vesicles from human sera and validating their brain-specific origin through various assays.

Potential Biases

Potential bias in the selection of biomarkers and the reliance on specific animal models for validation.

Limitations

The study primarily focused on APLP1 and did not explore other potential biomarkers in depth.

Participant Demographics

Included patients with glioblastoma multiforme and healthy volunteers.

Statistical Information

P-Value

p<0.001

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1126/sciadv.ado6894

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication